Merck & Co., Inc. (MRK)
Merck: A Golden Buying Opportunity
Keytruda continues to dominate, driving 50% of revenue, with new approvals and delivery methods strengthening MRK's oncology leadership. The company's long-term outlook is also promising, with a full pipeline of new final-stage drugs, an expanding vaccine portfolio, and breakthroughs in animal health products. Despite patent and regulatory risks, MRK's low valuation, strong balance sheet, and 3.8% dividend yield make it appealing for long-term investors.
Merck (MRK) Declines More Than Market: Some Information for Investors
In the closing of the recent trading day, Merck (MRK) stood at $84.81, denoting a -1.04% move from the preceding trading day.
Will Merck (MRK) Beat Estimates Again in Its Next Earnings Report?
Merck (MRK) has an impressive earnings surprise history and currently possesses the right combination of the two key ingredients for a likely beat in its next quarterly report.
Here's Why Merck (MRK) is a Strong Momentum Stock
The Zacks Style Scores offers investors a way to easily find top-rated stocks based on their investing style. Here's why you should take advantage.
Will Keytruda Continue to Aid Merck's Top Line in Q3 Earnings?
MRK's Keytruda remains its dominant growth engine and is expected to have boosted its top line in the third quarter.
High Margins, Lower Price: Is This Merck Stock's Buying Window?
Merck (MRK) stock merits your attention. Why? Because it offers monopoly-like high margins at a discounted price.
Merck (MRK) Declines More Than Market: Some Information for Investors
Merck (MRK) closed the most recent trading day at $87.61, moving 1.34% from the previous trading session.
Merck Rises 13% in a Week: Should You Buy, Sell or Hold the Stock?
MRK's stock witnesses an upside after Pfizer's pricing deal, but Gardasil's slump and Keytruda's looming LOE keep investors cautious.
Merck: A Race Against The Keytruda Clock
Merck (MRK) is attractively valued, boasting strong free cash flow, robust margins, and a leading position in oncology with Keytruda. MRK faces a looming patent cliff for Keytruda in 2028, but a strong late-stage pipeline and R&D investments offer long-term growth potential. Recent political developments reduce regulatory risks, and the company's diversified operations and pipeline help buffer near-term uncertainties.
MRK Stock Up Nearly 14% So Far This Week: What's Driving It?
Merck shares climb nearly 14% as Pfizer's landmark drug pricing deal with the Trump administration sparked renewed optimism in pharma stocks.
Is It Worth Investing in Merck (MRK) Based on Wall Street's Bullish Views?
When deciding whether to buy, sell, or hold a stock, investors often rely on analyst recommendations. Media reports about rating changes by these brokerage-firm-employed (or sell-side) analysts often influence a stock's price, but are they really important?
Big Pharma braces for the next price cut
Drugmakers know the script by now. Washington picks a handful of blockbuster medicines, haggles with their makers, and then publishes the “maximum fair price” that Medicare will pay.
